Stewart A. Factor
A5054911069- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- Genetic Neurodegenerative Diseases
- Schizophrenia research and treatment
- Cerebral Palsy and Movement Disorders
- Balance, Gait, and Falls Prevention
- Autism Spectrum Disorder Research
- Parkinson's Disease and Spinal Disorders
- Neurological diseases and metabolism
- Epilepsy research and treatment
- Neurological and metabolic disorders
- Pharmacological Effects and Toxicity Studies
- RNA regulation and disease
- Pharmaceutical studies and practices
- Attention Deficit Hyperactivity Disorder
- Nuclear Receptors and Signaling
- Glycogen Storage Diseases and Myoclonus
- Alzheimer's disease research and treatments
- Chemical Reactions and Isotopes
- Electroconvulsive Therapy Studies
- Restless Legs Syndrome Research
- Sleep and Wakefulness Research
- Dysphagia Assessment and Management
- Bipolar Disorder and Treatment
Emory University
2016-2025
Emory National Primate Research Center
2023
The Huntington Library, Art Museum, and Botanical Gardens
2022
Neurology, Inc
2022
The Neurological Institute
2020
Louis Stokes Cleveland VA Medical Center
2020
Michigan State University
2018
University of Alabama at Birmingham
2018
VA Puget Sound Health Care System
2010-2018
University of Washington
2018
There is mounting evidence for a connection between the gut and Parkinson's disease (PD). Dysbiosis of microbiota could explain several features PD.
<h3>Background</h3> The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear. <h3>Objective</h3> To compare initial treatment with pramipexole vs levodopa in disease, followed by supplementation, respect the development of motor complications, other adverse events, and functional quality-of-life outcomes. <h3>Design</h3> Multicenter, parallel-group, double-blind, randomized controlled trial. <h3>Setting</h3> Academic movement disorders clinics at 22 sites...
There are no standardized diagnostic criteria for psychosis associated with Parkinson's disease (PDPsy). As part of an NIH sponsored workshop, we reviewed the existing literature on PDPsy to provide that distinguish from other causes psychosis. Based these data, propose provisional in style Diagnostic and Statistical Manual Mental Disorders IV-TR. has a well-characterized temporal clinical profile hallucinations delusions, which is different than pattern seen psychotic disorders such as...
To determine the safety and efficacy of botulinum toxin type B (BoNT/B) in patients with A-resistant cervical dystonia (CD).Local intramuscular injections BoNT are an effective therapy for CD. After repeated use, some become resistant to therapy. BoNT/B, A toxin-responsive patients, is proposed as alternative patients.The authors performed a 16-week, double-blind, placebo-controlled trial BoNT/B resistance was confirmed frontalis-type test, placebo or 10,000 U administered single session...
<h3>Importance</h3> Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives may therefore lead to stable systemic exposure while preserving key pharmacological activity. <h3>Objective</h3> To evaluate efficacy safety of deutetrabenazine treatment control chorea associated with Huntington disease. <h3>Design, Setting, Participants</h3> Ninety ambulatory adults diagnosed manifest disease baseline total maximal...
Tardive dyskinesia is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotics. Valbenazine (NBI-98854) novel, highly selective vesicular monoamine transporter 2 inhibitor that demonstrated favorable efficacy and tolerability in the treatment of tardive phase studies. This 3 study further evaluated efficacy, safety, valbenazine as for dyskinesia.This 6-week, randomized, double-blind, placebo-controlled trial included patients with schizophrenia,...
Abstract It has been suggested that sleep may have a positive effect on morning motor symptoms in Parkinson's disease (PD). We examined this possibility and also looked at common disorders PD. Seventy‐eight PD patients 43 normal elderly subjects answered questionnaire. Of the patients, 43.6% reported improved morning, 37.2% worse, 19.2% unchanged compared to rest of day. No difference was found between morning‐better ‐worse groups with respect age, duration or stage PD; antiparkinsonian...
<h3>Importance</h3> We observed a significant correlation between cerebrospinal fluid (CSF) levels of tau proteins and α-synuclein, but not β-amyloid 1-42 (Aβ1-42), lower concentration CSF biomarkers, as compared with healthy controls, in cohort entirely untreated patients Parkinson disease (PD) at the earliest stage studied so far. <h3>Objective</h3> To evaluate baseline characteristics relationship to clinical features biomarkers (Aβ1-42, total [T-tau], phosphorylated threonine 181...
<h3>Objective:</h3> Age at onset of diagnostic motor manifestations in Huntington disease (HD) is strongly correlated with an expanded CAG trinucleotide repeat. The length the normal repeat allele has been reported also to influence age onset, interaction allele. Due profound implications for mechanism and modification, we tested whether allele, between alleles, or presence a second affects HD signs. <h3>Methods:</h3> We modeled natural log-transformed as function lengths alleles their by...
To evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) norepinephrine (SNRI) in treatment depression Parkinson disease (PD).A total 115 subjects with PD were enrolled at 20 sites. Subjects randomized to receive an SSRI (paroxetine; n = 42), SNRI (venlafaxine extended release [XR]; 34), or placebo (n 39). met DSM-IV criteria for depressive disorder, operationally defined subsyndromal depression, scored >12 on first 17 items Hamilton Rating Scale Depression...
To determine the efficacy and safety of deutetrabenazine as a treatment for tardive dyskinesia (TD).One hundred seventeen patients with moderate to severe TD received or placebo in this randomized, double-blind, multicenter trial. Eligibility criteria included an Abnormal Involuntary Movement Scale (AIMS) score ≥6 assessed by blinded central video rating, stable psychiatric illness, psychoactive medication treatment. Primary endpoint was change AIMS from baseline week 12. Secondary endpoints...
Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used integrative proteomics to identify cerebrospinal fluid (CSF) representing a wide spectrum AD pathophysiology. Multiplex mass spectrometry identified ~3500 ~12,000 proteins in CSF brain, respectively. Network analysis the brain proteome resolved 44 biologically modules, 15 which overlapped with proteome. markers these...
Objective A 12‐month double‐blind sham‐surgery–controlled trial assessing adeno‐associated virus type 2 (AAV2)‐neurturin injected into the putamen bilaterally failed to meet its primary endpoint, but showed positive results for endpoint in subgroup of subjects followed 18 months and several secondary endpoints. Analysis postmortem tissue suggested impaired axonal transport neurturin from substantia nigra. In present study, we tested safety efficacy AAV2‐neurturin delivered Methods We...
To assess the cognitive phenotype of glucocerebrosidase (GBA) mutation carriers with early-onset Parkinson disease (PD).We administered a neuropsychological battery and University Pennsylvania Smell Identification Test (UPSIT) to participants in CORE-PD study who were tested for mutations PARKIN, LRRK2, GBA. Participants included 33 GBA 60 noncarriers any genetic mutation. Primary analyses performed on 26 heterozygous without additional 39 age- PD duration-matched noncarriers. Five domains,...
Mutations associated with leucine-rich repeat kinase 2 are the most common known cause of Parkinson's disease. The expression in immune cells and its negative regulatory function nuclear factor activated T implicates development inflammatory environment characteristic aim this study was to determine pattern cell subsets correlate it immunophenotype from disease healthy subjects. For immunophenotyping, blood 40 patients 32 age matched-healthy control subjects were analyzed by flow cytometry....
Abstract In Parkinson’s disease (PD), gastrointestinal features are common and often precede the motor signs. Braak colleagues proposed that PD may start in gut, triggered by a pathogen, spread to brain. Numerous studies have examined gut microbiome PD; all found it be altered, but inconsistent results on associated microorganisms. Studies date been small ( N = 20 306) difficult compare or combine due varied methodology. We conducted microbiome-wide association study (MWAS) with two large...